Our Team

 

Management

Jingrong Jean Cui, Ph.D.

Scientific Founder, President and CEO

Dr. Jingrong Jean Cui is a renowned oncology drug designer who is the lead inventor of multiple oncology medicines and clinical compounds.  Dr. Cui is the scientific founder of Turning Point Therapeutics, Inc. (TP), a San Diego based biotech company focusing on turning point medicines for cancer patients.  TP went public on NASDAQ in April 2019 (Ticker: TPTX).  Dr. Cui served as TP’s Chief Scientific Officer (October 2013-January 2020) and a member of Board of Directors (October 2013-June 2020).  Prior to that, she was Senior Principal Scientist and then Associate Research Fellow at Pfizer (2003-2013). Prior to that, Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation (1999-2003).  

Dr. Cui has made significant contributions in oncology drug discovery and development.  As scientific founder of Turning Point, she focused on solving drug resistance issues in targeted therapies and invented a unique macrocyclic platform to systematically address resistance issues.  This novel strategy and approach led to the creation of three clinical compounds: Repotrectinib (TPX-0005), TPX-0022, and TPX-0046 within 6 years since founding the company.  Repotrectinib, a ROS1/TRK/ALK inhibitor, is now in Phase 1/2 global clinical trial.  TPX-0022, a MET/CSF1R/SRC inhibitor, and TPX-0046, a RET/SRC inhibitor, entered into Phase 1 studies in 2019.  At Pfizer, Dr. Cui was the lead inventor of Crizotinib (XALKORITM) and Lorlatinib (LORBRENATM), and worked on several other oncology projects, including SUTENTTM.

Dr. Cui and her Crizotinib chemistry team at Pfizer were selected for the 38th National Inventor of the Year Award in 2011.  She received two Pfizer Worldwide R&D Achievement Awards (2006 and 2012) and Pfizer innovation award in 2011.  Dr. Cui was an honoree for the 2013 American Chemical Society (ACS)’s Heroes of Chemistry Program for the discovery and development of Crizotinib.  Dr. Cui received her 2nd Heroes of Chemistry Award from ACS in 2021 for the discovery and development of Lorlatinib.  She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013.  

Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China.  She obtained her postdoctoral training at Lawrence Berkeley National Laboratory and the University of California Berkeley.

Yishan (Peter) Li, Ph.D., M.B.A.

Co-Founder, and Executive Chairman

Yishan (Peter) Li, Ph.D., M.B.A. is co-founder of Turning Point Therapeutics, Inc. (TP), a clinical-stage biotech company, listed on NASDAQ (Ticker: TPTX). Dr. Li served as Chairman and CEO of TP from October 2013 (founding) to September 2018 and continued to serve as a Director until TP completed a successful $191 million IPO on Nasdaq in April 2019. As Chairman and CEO, Dr. Li led TP for 5 years and successfully raised 4 rounds of venture financing for $147 million, in total, from leading biotech investors, Cormorant Asset Management, OrbiMed, S.R. One, Lilly Asia Ventures, Foresite Capital, venBio, HBM Partners, Nextech Invest, etc. TP has built a strong pipeline with the lead compound Repotrectinib entering pivotal Phase 2 clinical trial and two additional projects in clinical development (TPX-0022, TPX-0046).

Prior to TP, Dr. Li served as Executive Vice President at Epitomics, Inc., a leading antibody technology company specializing in rabbit monoclonal antibody development for reagent, diagnostics, and therapeutics (acquired by Abcam, plc in March 2012). Prior to Epitomics, Dr. Li was Vice President at Kenson Ventures, LLC. He served on Board of Directors and observers to the Board for biotech companies.

Dr. Li was a postdoctoral research fellow at the Department of Molecular and Cell Biology, University of California, Berkeley. He earned his M.B.A. from Haas School of Business, University of California, Berkeley. He received his Ph.D. in biochemistry from the Ohio State University, where he was a University Presidential Fellow, and his B.S. from University of Science and Technology of China.

Eugene Y. Rui, Ph.D.

Vice President, Chemistry

Eugene Rui is the Vice President of Chemistry at BlossomHill Therapeutics. Prior to joining BlossomHill, Eugene was an Associate Research Fellow in Oncology Chemistry Design at Pfizer La Jolla. During his nearly 25 years tenure at Pfizer, Eugene had led numerous projects, designed, and synthesized drug molecules to address unmet needs in the fields of oncology, antiviral and ophthalmology and contributed as a key designer to the delivery of 4 compounds (PF-0477736, PF-06821497, PF-06873600, PF-06939999) into clinical development. In addition, Eugene was the recipient of Pfizer’s La Jolla Discovery Innovation Award in 2006 for the design and synthesis of PF-04348733 for CAI project. Eugene received his BS in chemistry and MS in organic chemistry, both from Peking University. After working at Chinese Academy of Sciences for 2 years, Eugene came to the U.S. where he earned his Ph.D. at Purdue University in 1996. Eugene Rui is an inventor on 19 US patents and co-author on 28 publications. In his spare time, Eugene loves walking with his wife in their beautiful neighborhood and playing with their dog Muffin.

Board of Directors

Bihua Chen

Bihua Chen is the founder of Cormorant Asset Management, LP (“Cormorant”), an investment firm focused on innovative biotech, medtech and life science companies with assets under management of over $3bn. Ms. Chen manages Cormorant’s public fund as well as its private funds. Prior to founding Cormorant, Ms. Chen managed a separately managed account focused on the healthcare sector as a sub-adviser to a large, multi-strategy hedge fund based in New York. Ms. Chen obtained an MBA from the Wharton School of Business and a Master of Science, Molecular Biology, from the Graduate School of Biomedical Science at Cornell Medical College. Ms. Chen also holds a Bachelor of Science degree in Genetics and Genetic Engineering from Fudan University, Shanghai, China.

Jingrong Jean Cui, Ph.D.

Scientific Founder, President and CEO

(See Management)

Carl L. Gordon, Ph.D., CFA

Carl L. Gordon, Ph.D., CFA, is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm.  Dr. Gordon currently serves on the boards of directors of several public and private companies. He received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.

George J. Lee, Ph.D

George J. Lee, Ph.D. is a general partner and co-founder of Hercules Bioventure Partners, LLC, a venture management company specializing in investments in the biotech and pharmaceutical fields. Hercules Bioventure Partners has been dedicated to building a strong biotech portfolio in regions of the US and Asia over the last decade. Dr. Lee has extensive experience in the pharmaceutical industry having worked productively at a major pharmaceutical company (Syntex) and early-stage biomedical companies for years. Dr. Lee is an internationally known pioneer in the field of steroid hormones research. Dr. Lee has in depth experience in analytical methods development and validation for New Drug Application (NDA) as well as various applications to the Food & Drug Administration. Dr. Lee earned his Ph.D. degree in chemistry from the State University of New York at Buffalo and his B.S. degree in agricultural chemistry from National Taiwan University, Taiwan.

Yishan (Peter) Li, Ph.D., M.B.A.

Co-Founder, and Executive Chairman

(See Management)